PT851753E - Composicoes em aerossol - Google Patents

Composicoes em aerossol

Info

Publication number
PT851753E
PT851753E PT96931227T PT96931227T PT851753E PT 851753 E PT851753 E PT 851753E PT 96931227 T PT96931227 T PT 96931227T PT 96931227 T PT96931227 T PT 96931227T PT 851753 E PT851753 E PT 851753E
Authority
PT
Portugal
Prior art keywords
liquefied hydrofluoroalkane
fatty acid
active ingredient
medium
chain fatty
Prior art date
Application number
PT96931227T
Other languages
English (en)
Inventor
Takehisa Hata
Fumio Shimojo
Saburo Murata
Yuji Tokunaga
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of PT851753E publication Critical patent/PT851753E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PT96931227T 1995-09-19 1996-09-18 Composicoes em aerossol PT851753E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23934295 1995-09-19

Publications (1)

Publication Number Publication Date
PT851753E true PT851753E (pt) 2004-04-30

Family

ID=17043318

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96931227T PT851753E (pt) 1995-09-19 1996-09-18 Composicoes em aerossol

Country Status (16)

Country Link
US (2) US6361760B1 (pt)
EP (1) EP0851753B1 (pt)
JP (2) JP3266005B2 (pt)
KR (1) KR100523754B1 (pt)
CN (1) CN1137680C (pt)
AT (1) ATE254450T1 (pt)
AU (1) AU719613B2 (pt)
CA (1) CA2232378C (pt)
DE (1) DE69630798T2 (pt)
DK (1) DK0851753T3 (pt)
ES (1) ES2206590T3 (pt)
HK (1) HK1017845A1 (pt)
PT (1) PT851753E (pt)
TW (1) TW429153B (pt)
WO (1) WO1997010806A1 (pt)
ZA (1) ZA967887B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041191A1 (fr) * 1997-03-14 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Preparation pour aerosol
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
CN1668733A (zh) * 2002-05-30 2005-09-14 细胞基因公司 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法
EP1539157B1 (en) 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
AU2002952559A0 (en) * 2002-11-08 2002-11-21 Fujisawa Pharmaceutical Co., Ltd. New use
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US20040230272A1 (en) * 2003-04-11 2004-11-18 Cates Adam W. Subcutaneous lead with temporary pharmacological agents
MXPA05013324A (es) * 2003-06-10 2006-03-09 Astellas Pharma Inc Preparacion de aerosol comprendiendo un anexo que incluye una composicion de aerosol conteniendo compuesto macrolido.
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
JP2007510671A (ja) * 2003-11-06 2007-04-26 セルジーン・コーポレーション アスベスト関連疾患および障害の治療および管理のための、ｊｎｋ阻害剤の使用方法およびそれを含む組成物
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
JP2007516951A (ja) * 2003-12-30 2007-06-28 アステラス製薬株式会社 気道閉塞症の治療または予防のためのマクロライドの使用
BRPI0518255A2 (pt) * 2004-11-23 2008-11-11 Celgene Corp mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007112052A2 (en) * 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
US7741446B2 (en) 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
US9044391B2 (en) * 2007-01-10 2015-06-02 Board Of Regents, The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2997976A1 (en) * 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
MX2011004730A (es) * 2008-11-04 2011-05-30 Cipla Ltd Composicion farmaceutica en aerosol.
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
EP3461889A1 (en) 2009-11-19 2019-04-03 Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
US20110318277A1 (en) * 2010-06-25 2011-12-29 APT Pharmaceuticals, Inc. University of Maryland, Baltimore Tacrolimus compositions for aerosol administration
JP6266529B2 (ja) 2011-12-02 2018-01-24 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおけるアリールスルファターゼａ活性を増加するための方法および組成物
US20150023956A1 (en) 2013-07-22 2015-01-22 Armagen Technologies, Inc. Methods and compositions for increasing enzyme activity in the cns
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
IE66485B1 (en) 1989-07-05 1996-01-10 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
PH31204A (en) 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
ATE183083T1 (de) 1992-11-18 1999-08-15 Fujisawa Pharmaceutical Co Pharmazeutische zubereitung mit verlängerter wirkung
JPH06345646A (ja) 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US5681501A (en) * 1995-10-11 1997-10-28 E. I. Du Pont De Nemours And Company Compositions including a hydrofluoropropane
WO1998041191A1 (fr) * 1997-03-14 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Preparation pour aerosol
CN1259053A (zh) 1997-04-11 2000-07-05 藤泽药品工业株式会社 药物组合物

Also Published As

Publication number Publication date
WO1997010806A1 (en) 1997-03-27
CA2232378A1 (en) 1997-03-27
US6524556B2 (en) 2003-02-25
DE69630798T2 (de) 2004-09-23
CN1137680C (zh) 2004-02-11
EP0851753B1 (en) 2003-11-19
TW429153B (en) 2001-04-11
CN1201384A (zh) 1998-12-09
JP3266005B2 (ja) 2002-03-18
HK1017845A1 (en) 1999-12-03
US6361760B1 (en) 2002-03-26
CA2232378C (en) 2009-04-14
DK0851753T3 (da) 2004-03-15
EP0851753A1 (en) 1998-07-08
KR19990044656A (ko) 1999-06-25
JP3362394B2 (ja) 2003-01-07
AU719613B2 (en) 2000-05-11
ZA967887B (en) 1997-04-07
AU6999896A (en) 1997-04-09
ATE254450T1 (de) 2003-12-15
KR100523754B1 (ko) 2007-06-04
US20020061906A1 (en) 2002-05-23
JPH09143054A (ja) 1997-06-03
DE69630798D1 (de) 2003-12-24
ES2206590T3 (es) 2004-05-16
JP2000505050A (ja) 2000-04-25

Similar Documents

Publication Publication Date Title
PT851753E (pt) Composicoes em aerossol
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
AR021922A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.
GB2062465B (en) Topical preparation containing nitroglycerine and optionally other medicaments
BR9805993A (pt) Composição farmacêutica de aerosol.
YU86001A (sh) Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
NZ330369A (en) aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester
KR930007444A (ko) 4-비페닐아세트 산(bpaa)를 함유하는 제약학적 조성물
MX9606501A (es) Composiciones antifungosas y curativas para heridas y metodos para preparar y utilizar las mismas.
AU2001288460A1 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
GR3030528T3 (en) Viscoelastic compositions of fluorinated organic compounds
MX9606502A (es) Composiciones antiqueratoliticas y curativas para heridas y metodos para preparar y utilizar las mismas.
JPS5659710A (en) Preventive and remedy for psoriasis
FI962056A0 (fi) Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan
IT1255076B (it) Microsfere biodegradabili ad uso farmaceutico e cosmetico
EP0968713A4 (en) PATCHES CONTAINING ISOSORBID NITRATE
AU8740198A (en) Inhibitor and preservative formulation
EP0966958A4 (en) AEROSOL PREPARATION
MY105086A (en) Liquid detergent composition.
ES456094A1 (es) Un procedimiento para la preparacion de 2-acetoxi-benzoato de 2-(carbamoil) fenilo.
ES2085657T3 (es) Un medicamento de accion retardada que contiene flurbiprofeno y su utilizacion.
AU528211B2 (en) Synergistic analgesic compositions of suprofen
JPS5762220A (en) Embrocation for external use
ATE206048T1 (de) Zur topischen applikation bestimmte diclofenac- lösung
LT2001072A (lt) Maisto papildas